Quell Therapeutics

Explore our ongoing LIBERATE Study for people who have received a liver transplant

Explore our ongoing LIBERATE Study for people who have received a liver transplant

LIBERATE is a Phase I/II clinical study for adults who have had a liver transplant in the last 1-5 years and are taking immunosuppressant drugs

Quell patients banner image

Introducing our science and our study

A liver transplant can be life changing - it offers the prospect of a more normal way of living. However, people who receive a liver transplant need to take a combination of immunosuppressant drugs to prevent the body from rejecting the organ – usually for the rest of their lives. Immunosuppressant drugs are effective, but they work by ‘damping down’ the entire immune system. This reduces the body’s natural defences, which increases the risk of infections or other serious conditions, including some types of cancer. 

This page has been developed to help explain the science behind a potential new treatment that aims to remove the need for lifelong immunosuppressants for people who have received a liver transplant. It also introduces the clinical study that investigates how the treatment works in people with a liver transplant. If you or a loved one are interested in taking part in the study, please speak to your doctor.

Frequently Asked Questions

Find answers to your questions here

© 2025 Quell Therapeutics